Wegovy review: is it worth it?
Wegovy (semaglutide 2.4mg) is an FDA-approved once-weekly injection for adults with obesity or overweight with comorbidities.
Editor's Choice
Strong, well-studied weight loss with real trade-offs
Wegovy is among the most effective FDA-approved weight-management medications, with average weight loss near 15% of body weight in pivotal trials and a documented 20% reduction in heart attack, stroke, and cardiovascular death in adults who have established cardiovascular disease and are overweight or obese (but do not have diabetes). It is not a quick fix: it requires weekly injections (or a newer daily pill), causes gastrointestinal side effects in most users, and works only as long as you keep taking it. For the right candidate willing to commit, the evidence base is strong, but the decision should be made with a prescriber.
Check PriceFrom $1349/mo
Pros
- ✓Among the most effective FDA-approved weight-loss medications, with about 15% average body-weight reduction in large randomized trials (STEP 1 and STEP 5)
- ✓Documented cardiovascular benefit: a 20% reduction in heart attack, stroke, and cardiovascular death in adults with established heart disease who are overweight or obese (SELECT trial)
- ✓Once-weekly injection, with a newer once-daily oral pill option approved in December 2025 for patients who prefer to avoid needles
- ✓Weight loss is sustained over 2 years with continued use, and the drug also tends to improve blood pressure, blood sugar, and waist circumference
- ✓Backed by an extensive, high-quality evidence base (the STEP and SELECT programs) and a clearly defined FDA-approved label and safety profile
Cons
- ✕Frequent gastrointestinal side effects (nausea, diarrhea, vomiting, constipation), especially during dose increases
- ✕Weight is commonly regained after stopping; a STEP 1 extension found people regained about two-thirds of their lost weight within roughly a year, making it effectively a long-term commitment
- ✕Ongoing cost and inconsistent coverage: about $349 per month cash for standard doses in 2026 (list price near $1,350), and many insurers, including most government plans, do not cover it for weight loss
- ✕Carries a boxed warning for thyroid C-cell tumors and is contraindicated for people with a personal or family history of medullary thyroid cancer or MEN 2
- ✕Requires gradual dose titration over about 4 months and ongoing medical supervision; it is not a fast or one-time solution
How it works
Wegovy's active ingredient, semaglutide, mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). By activating GLP-1 receptors in the brain's appetite centers, it reduces hunger, increases feelings of fullness, and slows how quickly the stomach empties. The result is that most people naturally eat less and feel satisfied on smaller portions. It also improves how the body handles blood sugar. Because it does not "burn fat" directly, it works largely by lowering calorie intake, which is why diet and physical activity remain part of treatment.
Active ingredient: Semaglutide
Effectiveness
In the pivotal STEP 1 trial (NEJM, 2021; 1,961 adults with overweight or obesity but without diabetes), weekly semaglutide 2.4 mg produced an average weight loss of about 14.9% of body weight at 68 weeks versus roughly 2.4% with placebo, and about 86% of treated participants lost at least 5% of their body weight. The 2-year STEP 5 trial (Nature Medicine, 2022) showed sustained results with continued use: about 15.2% mean weight loss versus 2.6% with placebo at 104 weeks. In the large SELECT cardiovascular outcomes trial (NEJM, 2023; 17,604 adults with established cardiovascular disease, overweight or obese, without diabetes), semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% versus placebo (hazard ratio 0.80). The newer oral Wegovy 25 mg pill produced about 16.6% mean weight loss among participants who adhered to treatment in the OASIS 4 trial. Individual results vary.
Side effects
The most common side effects (each occurring in 5% or more of users in trials) are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, and indigestion, along with headache, fatigue, and dizziness. These are usually mild to moderate, tend to be worst when starting or increasing the dose, and often ease over a few weeks. Serious but less common risks include pancreatitis, gallbladder problems (including gallstones), acute kidney injury from dehydration caused by vomiting or diarrhea, low blood sugar (mainly in people also taking diabetes medications such as insulin or sulfonylureas), and worsening of diabetic eye disease. Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek medical care promptly for severe, persistent abdominal pain (a possible sign of pancreatitis). This is not a complete list; review the full label and discuss risks with your prescriber.
- Nausea · common
- Diarrhea · common
- Constipation · common
- Pancreatitis · serious
- Gallbladder problems · uncommon
Cost
Starts at $1349/mo from Novo Nordisk.
As of 2026, Wegovy's list price is roughly $1,350 per month before insurance or discounts. Through Novo Nordisk's NovoCare self-pay program, eligible cash-paying patients without insurance can get the injection for about $349 per month for standard doses, with a limited-time promotional price near $199 per month for the lowest starter doses (0.25 mg and 0.5 mg) through mid-2026; the oral pill has its own self-pay pricing, generally lower. This self-pay price was lowered over time (it was about $499 per month in early 2025). With commercial (non-government) insurance that covers Wegovy, the manufacturer savings card can bring copays as low as $0 for eligible patients, but many plans, and most Medicare and Medicaid plans, still do not cover Wegovy for weight loss. Coverage and out-of-pocket costs vary widely and change frequently, so verify current pricing for your specific dose and plan directly with NovoCare and your pharmacy.
Is it worth it?
Wegovy delivers some of the strongest non-surgical weight-loss results available, backed by large randomized trials and a documented cardiovascular benefit in one high-risk population. The trade-offs are real: frequent GI side effects, ongoing cost if uninsured, and weight regain when you stop. For people with obesity, or overweight plus a weight-related condition, it is one of the most effective options available in 2026 if you can sustain it. This is a prescription medication; only a clinician can decide whether it is right for you.
Frequently asked questions
How much weight can you lose on Wegovy?
In the pivotal STEP 1 trial, adults with overweight or obesity but without diabetes lost an average of about 15% of their body weight over 68 weeks on weekly semaglutide 2.4 mg, compared with about 2% on placebo. About 86% of treated participants lost at least 5% of their weight. Individual results vary, and weight loss is greatest when the medication is combined with a reduced-calorie diet and increased activity.
What is the difference between Wegovy and Ozempic?
Both Wegovy and Ozempic contain the same active drug, semaglutide, but they are approved for different uses. Wegovy is FDA-approved for chronic weight management at a higher maximum dose (2.4 mg), while Ozempic is approved for type 2 diabetes (maximum 2 mg). They are not interchangeable and use different pens and dosing schedules. Your prescriber decides which, if either, is appropriate.
How much does Wegovy cost without insurance in 2026?
Wegovy's list price is roughly $1,350 per month. As of 2026, Novo Nordisk's NovoCare self-pay program offers the injection to eligible cash-paying patients for about $349 per month for standard doses, with a limited-time promotional price near $199 per month for the lowest starter doses through mid-2026. With commercial insurance that covers Wegovy, the manufacturer savings card can lower copays for eligible patients, but many plans do not cover it for weight loss. Prices change often, so confirm current pricing with NovoCare and your pharmacy.
What happens when you stop taking Wegovy?
Most people regain a significant portion of their lost weight after stopping, because appetite and hunger signals return toward baseline. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within roughly a year of stopping. For this reason, Wegovy is generally considered a long-term treatment rather than a short course. Talk to your prescriber before changing or stopping the medication.
What are the most common side effects of Wegovy?
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. They are usually mild to moderate, tend to be worst when the dose is being increased, and often improve within a few weeks. Less common but serious risks include pancreatitis and gallbladder problems. Seek medical care for severe, persistent abdominal pain, and review the full label with your prescriber.
Who should not take Wegovy?
Wegovy should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or by those with a known serious allergy to semaglutide. It should not be used during pregnancy and, because of the drug's long half-life, the label advises stopping at least 2 months before a planned pregnancy. People with a history of pancreatitis, gallbladder disease, or kidney problems should use it cautiously and only under medical supervision.
Is there a Wegovy pill, and how does it compare to the injection?
Yes. The FDA approved an oral Wegovy 25 mg tablet on December 22, 2025, with a US launch in early 2026. In the OASIS 4 trial it produced about 16.6% mean weight loss among participants who adhered to treatment, broadly comparable to the injection, but it must be taken daily on an empty stomach with strict timing rules (no other food, drink, or medication for 30 minutes after). Your prescriber can advise which form suits you.
How long does it take for Wegovy to start working?
Many people notice reduced appetite within the first few weeks, but the dose is increased gradually over about 16 weeks, and meaningful weight loss typically builds over several months. In the pivotal trials, the largest results were measured at 68 weeks and beyond, so it is best viewed as a long-term treatment.
Does Wegovy reduce heart attack and stroke risk?
Yes, in a specific group. The SELECT trial of 17,604 adults who had established cardiovascular disease and were overweight or obese (without diabetes) found that Wegovy reduced major cardiovascular events (cardiovascular death, non-fatal heart attack, and non-fatal stroke) by 20% versus placebo. This led to an FDA-approved cardiovascular indication for adults with established heart disease who are overweight or obese. The benefit has not been demonstrated in lower-risk groups.
Sources
- Wegovy (semaglutide) Prescribing Information / FDA Label — DailyMed, U.S. National Library of Medicine (2025)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (via PubMed) (2021)
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial — Nature Medicine / PubMed Central (2022)
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — New England Journal of Medicine (2023)
- Wegovy pill (oral semaglutide 25 mg) FDA approval announcement — Novo Nordisk (2025)
- Wegovy Cost & Coverage Information (NovoCare self-pay pricing) — Novo Nordisk (NovoCare) (2026)